OTCReporter.com: ICBS to focus on pharmaceutical and environmental markets
|
|
Issue# 1520 |
|
| ICBS to focus on pharmaceutical and environmental markets |
NEW YORK, MONTREAL, and SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ – ICBS Ltd., (OTCPK: ICBT), board of directors, announced that the company will focus its efforts on the pharmaceutical market through its subsidiary, Canadian Bio Med Systems Ltd., and the environmental market through its partnership with BioSpec Global Solutions Inc., of Quebec.
High Interest in a New Approach
“We feel that at this point, we should concentrate on the most promising investments and that is with Canadian Bio Med Systems and BioSpec Global Solutions. We have therefore decided to cease offering business consulting services through our subsidiary, Inter Canadian Business Services along with divesting our interest in Ramapo Valley Brewery” said Dr. George Tsoukas, Chairman.
ICBS has positioned itself with 51% ownership in Canadian Bio Med Systems and 25% interest in BioSpec Global Solutions.
These companies have entered a multi billion dollar market place in recession proof industries.
ICBS will continue to acquire undervalued opportunities in these selective high-growth industries to create value for our shareholders and target partners by combining expertise in both the product and capital markets. Taking interest in companies to align with their long-term interest and help build enduring value for our investors.
Canadian Bio Med Systems, has acquired the licensing rights to two new potentially revolutionary drugs in the billion dollar ophthalmic arena. The drug for the treatment of Glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world, and Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.
BioSpec Global Solutions has developed state-of-the-art technologies for rapid, onsite (remote) monitoring of microbial contamination in drinking water, recreational water, agriculture food production, pharmaceuticals and medical applications. TOGS(TM) 9000 instrument is a single test, precision, portable incubator utilizing the patented technology provide on-site testing of microbial contamination in drinking water. Used in conjunction with a chromogenic reagent, it provides an accurate, virtually fool-proof microbial test for field, rural and remote applications in the detection of Total Coliforms and E.coli to WHO standards using globally approved methods (USEPA, AWWA-APHA). The company holds world wide patents
|
ICBS LIMITED |
|
|
ICBS LIMITED (ICBT)
ICBS Limited specializes in mergers and acquisitions (M&A) advisory services and invests in selective businesses with potential for high growth. |
|||||||||||
ICBS Limited
Phone: 514-932-4402 |
Similiar Companies in Sector ·
·
|
| Current Projects |
 |
Canadian Bio Med Attacks World’s Leading Cause of Blindness Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., and Ocular Therapeutics Inc. of San Diego California, announced the development of a new AMD drug now being tested by Canadian Bio Med Systems, Inc. (CBMS). Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The drug under development by Canadian Bio Med Systems, has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products |
ICBS acquires 25% interest in BioSpec Global Solutions Inc.
|
| Company Overview |
|
ICBS Limited ICBS · · ·
ICBS
ICBS Companies , Partnerships & Interests Canadian Bio Med Canadian Bio Med Systems Canadian Bio Med Systems Glaucoma is a leading cause of blindness in the United States and the world.The current treatment for Glaucoma consists of eye drops usually used one, two or more times each day.Usually more than one drug is prescribed.Due to the frequency of applications required, the largest problem is with patient compliance.The drug under development by CBMS at the University of Arizona has the remarkable prospect of needing to be used only once or twice per year by the patient. The market for Glaucoma treatment is huge.It is projected that by 2010 there will be 60.5 million people with the most common form of Glaucoma. Novartis alone sells over $1.5 billion of Glaucoma medications annually. AMD is the leading cause of blindness worldwide, for people over 55 years of age.There is currently no cure for the disease. Several large companies are working with product development drugs which are still experimental and extremely expensive.The drug under development by CBMS has the benefits of requiring fewer treatments then current drugs, and will be far less expensive. There is extensive intellectual property with U.S .and world patents issued and pending. Ramapo Valley Brewery Ramapo Valley Brewery New York
Their unique brewing process and Recipes, along with the use of the valley spring waters, resulted in award winning beers. Over the next three years , the demand for their beers grew at such an astounding rate that the founders, decided to make the transition to a formal brewery, and Ramapo Valley Brewery was born.
RVB is the only Kosher certified brewery in the United States , and certified to produce Kosher for Passover beer. R.V.B brews some of the worlds most exciting beers including the award winning gluten free Honey Beer iTrend ICBS holds a 50% interest iTrend has developed a market investment Artificial Intelligence system that assists investors. iTrend The development of our software was primarily an innovation spin-off from a Canadian university project. Our development team included students and developers supervised by a professor which worked on the project for over 3 years. Today, the research using genetic algorithm to manage funds continue and the lead designer is working as a trader in US and Hong Kong stocks. Most people invest by experience: learning from one’s own successful or failed investment decisions in the past. There are several drawbacks of such style of investment: · · · iTrend Bio Spec Global Solutions ICBS Ltd. has acquired twenty- five percent interest in BioSpec Global Solutions Inc., who has developed The TOGS 9000 is a bio-photonic incubation/detection instrument which quantifies microbial contamination. The analysis results can be obtained directly on-site through a computer or can be directly connected and controlled by an appropriate laboratory and or regulatory authority in a secure monitoring system using ‘AGACSSTM’(TM) software and the internet. As an example, The EPA could literally monitor all drinking water sources down to the individual well owner and do it quickly, accurately and cost effectively. Or the Center for Infectious Diseases ( CID ) could monitor the spread of antibiotic resistant microbes (ARMs) across the U.S. at the patient level. Doctors could determine the effectiveness of an antibiotic in their office for their patients before prescribing the antibiotic rather than the try and hope method presently used. The healthcare system could save hundreds of millions of dollars and hospital/doctor liabilities reduced. This technology is revolutionary for a global market. BIOSPEC believes the progression of this technology is leading towards wireless data transmission. Connecting the AQUASURE 9000 to a cell phone like device for data transmission to a laboratory much the same way pictures are sent by a cell phone will be cost effective, allowing the technology to penetrate the huge consumer market which presently isn’t addressed. BIOSPEC technology is recognized as the method for the detecting of microbial contamination. By entering in to a series of license agreements with well positioned companies LEADERSHIP George Tsoukas, Chairman |
| Market Snapshot |
|
|
| News |
OTC Reporter.com, LLC is an independent electronic publication, which provides industry data and information on publicly traded companies for the use of our readers. All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by OTCReporter .com , LLC to be accurate, and should not be considered to be all-inclusive. The company that is discussed in this profile has approved the statements made in this profile. This profile contains forward-looking statements that involve risks and uncertainties. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward looking statements. Statements in this press release about the company’s future expectations other than historical facts, are “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Reform Act of 1995. . Investors are cautioned that any information in this communication contains certain such forward-looking statements that involve substantial risks and uncertainties. When used, the words “anticipate,” “believe,” “estimate,” “expect,” and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements. The company’s actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward looking statements. Such “forward-looking statements” are subject to risks and uncertainties set forth from time to time in the company’s SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informational purposes only and should NOT be construed as an offer or solicitation of an offer to buy or sell any securities. OTCReporter .com , LLC may liquidate any securities issued when deemed appropriate to do so. Such liquidation may have a negative impact on the securities being liquidated. OTCReporter .com , LLC is not a licensed broker, broker dealer, market marker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.otcreporter.com. OTCReporter.com, LLC and/or its affiliates have received six million three hundred thirty thousand free trading shares from a third party. To date, six million three hundrd thirty thousand free trading shares have been sold. OTCReporter.com, LLCs affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. OTCReporter.com, LLC does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
We are vitally concerned with your privacy on the internet.
If you wish to be omitted from future distributions, please click here.
Your email address will be purged permanently from this database.
We take part in responsible email marketing and respect your right to refuse any other email distributions.
FROM: OTCReporter.com
PHONE# (732) 219-8819
ADDRESS: PO BOX 273 Rumson, NJ 07760
